ArticleScientific reports2026
Utilizing AI CAD for early pandemic screening in chest radiographs.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the potential application of existing artificial intelligence (AI) software in diagnosing COVID-19 (coronavirus disease 2019) and other pneumonia-related radiographic findings with the unprecedented challenge by COVID-19 pandemic, leveraging pre-trained commercial AI software originally designed for detecting pulmonary nodules in chest radiographs, we assessed its performance using public dataset comprising chest radiographs collected during the early stages of pandemic. The software demonstrated promising results, achieving a sensitivity of 86.83% and a specificity of 59.59% in detecting pneumonia features, including those caused by COVID-19. Considering only posterior-anterior (PA) radiographs, AI software exhibited improved performance, with sensitivity 89.16% and specificity 67.41%. The findings suggest the AI CAD software could serve as a triage for initial screening of infectious pulmonary diseases, especially in regions with limited access to advanced medical resources. This study underscores the importance of promptly adapting existing AI CAD to address urgent healthcare needs during infectious disease outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.